The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.
 
Gregory Russell Pond
No Relationships to Disclose
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Argos Therapeutics; Bayer; Genentech; Merck; Novartis; Pfizer; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Onyx (Inst)
Other Relationship - Boehringer Ingelheim
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Stephanie Anne Mullane
No Relationships to Disclose
 
Andrea Necchi
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Pierre Fabre; Seagen
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Celgene; Merck Sharp & Dohme; Roche
 
Daniele Raggi
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Astellas Pharma; Pfizer
Consulting or Advisory Role - Astellas Pharma
Research Funding - Bayer; Exelixis; Janssen; Novartis; Pfizer
 
Soonil Lee
No Relationships to Disclose
 
Joe Simpson
Employment - Genentech
 
Christina Louise Derleth
Employment - Genentech
 
Shih-Wen Lin
Employment - Genentech
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech